Previous Close | 5.0300 |
Open | 5.0500 |
Bid | 4.8000 x 800 |
Ask | 4.9800 x 800 |
Day's Range | 4.8900 - 5.0500 |
52 Week Range | 4.4100 - 10.3000 |
Volume | |
Avg. Volume | 919,393 |
Market Cap | 118.209M |
Beta (5Y Monthly) | 0.32 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.1430 |
Earnings Date | Jun 29, 2020 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 30.67 |
Subscribe to Yahoo Finance Plus to view Fair Value for ATNM
Here is how Alkermes (ALKS) and Actinium Pharmaceuticals (ATNM) have performed compared to their sector so far this year.
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company) a leader in the development of targeted radiotherapies for patients with unmet needs today highlighted data from full patient enrollment in the pivotal Phase 3 SIERRA trial of Iomab-B was presented in an oral presentation at the upcoming Transplantation & Cellular Therapy (TCT) Tandem Meetings of ASTCT and CIBMTR, the combined annual meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company) a leader in the development of targeted radiotherapies for patients with unmet needs today highlighted its activity at the upcoming Transplantation & Cellular Therapy (TCT) Tandem Meetings of ASTCT and CIBMTR, the combined annual meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR) being held April 23 – 26, 2022 v